Merck Sharp & Dohme 8-K Merck Reports Double-Digit Revenue and Earnings-Per-Share Growth for Third-Quarter 2007

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2007

EQUITY INCOME FROM AFFILIATES (millions of dollars)

	3Q `07			3Q `06			YTD 2007			YTD 2006
MERCK / SCHERING-PLOUGH	$	(480.9	)	$	(350.1	)	$	(1,293.1	)	$	(858.1	)
ASTRAZENECA LP		(181.2	)		(173.7	)		(608.3	)		(602.6	)
Other (1)		(106.4	)		(71.6	)		(278.8	)		(249.5	)
TOTAL	$	(768.5	)	$	(595.4	)	$	(2,180.2	)	$	(1,710.2	)

⁽¹⁾ Primarily reflects results for Merial Limited, and joint ventures with Sanofi Pasteur and Johnson & Johnson.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.

Merial	3Q `07		3Q `06		YTD 2007		YTD 2006
IVOMEC, HEARTGARD, other avermectins	$	112.8	$	111.5	$	366.7	$	362.0
FRONTLINE		241.7		217.1		866.1		732.6
BIOLOGICALS		162.0		143.5		472.8		435.6
Other Animal Health		66.7		61.4		192.0		175.4
TOTAL MERIAL SALES	$	583.2	$	533.5	$	1,897.6	$	1,705.6

Sanofi Pasteur-MSD	3Q `07		3Q `06		YTD 2007		YTD 2006
HEPATITIS VACCINES	$	18.0	$	17.8	$	53.9	$	54.3
VIRAL VACCINES		20.7		24.9		65.0		69.6
Other Vaccines(1)		400.6		187.0		780.0		455.6
TOTAL SANOFI PASTEUR-MSD SALES	$	439.3	$	229.7	$	898.9	$	579.5

⁽¹⁾ Includes sales ofGardasilof $137.0 million in 3Q07 and $245.0 million for the first nine months of 2007.

Merck / Schering-Plough Collaboration	3Q `07		3Q `06		YTD 2007		YTD 2006
VYTORIN	$	693.0	$	526.6	$	2,003.2	$	1,402.4
ZETIA		607.0		501.9		1,728.5		1,392.7
TOTAL MERCK / SCHERING-PLOUGH SALES	$	1,300.0	$	1,028.5	$	3,731.7	$	2,795.1

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	3Q `07			3Q `06			YTD 2007			YTD 2006
INTEREST INCOME	$	(186.9	)	$	(195.0	)	$	(540.9	)	$	(564.6	)
INTEREST EXPENSE		91.5			87.7			297.2			277.8
EXCHANGE GAINS		(8.3	)		(11.5	)		(39.8	)		(4.5	)
MINORITY INTERESTS		30.6			30.7			92.0			90.7
Other, net		(107.8	)		(46.6	)		(329.7	)		(104.8	)
TOTAL	$	(180.9	)	$	(134.7	)	$	(521.2	)	$	(305.4	)

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2007

NET PRODUCT SALES DETAIL (millions of dollars)

	3Q `07 vs. 3Q `06
	TOTAL			TOTAL		U.S.			U.S.		Foreign			Foreign
PRODUCT	% CHG			$		% CHG			$		% CHG			$
COZAAR / HYZAAR		—			814		-6	%		301		4	%		513
FOSAMAX		-6	%		725		-5	%		471		-8	%		254
SINGULAIR		17	%		1,018		14	%		718		27	%		300
ZOCOR		-41	%		218		-64	%		55		-26	%		163
Vaccines:
GARDASIL		*			418		*			328		*			91
ROTATEQ		*			171		*			161		*			10
ZOSTAVAX		*			61		*			61		N/A			—
OTHER VIRAL VACCINES(1)		73	%		428		78	%		412		2	%		16
HEPATITIS VACCINES		—			68		4	%		57		-18	%		11
OTHER VACCINES		-1	%		97		-4	%		79		17	%		18
Other Reported Products:
AGGRASTAT		-5	%		21		N/A			—		-5	%		21
ARCOXIA		15	%		76		N/A			—		15	%		76
CANCIDAS		6	%		135		-25	%		34		24	%		101
COSOPT / TRUSOPT		3	%		197		-7	%		86		13	%		111
CRIXIVAN / STOCRIN		-13	%		72		-28	%		5		-12	%		67
EMEND		20	%		49		3	%		33		84	%		16
INVANZ		36	%		50		22	%		27		57	%		23
JANUVIA		*			185		*			171		*			14
JANUMET		*			19		*			17		*			1
MAXALT		19	%		125		22	%		86		13	%		39
PRIMAXIN		2	%		186		-15	%		47		10	%		139
PROPECIA		12	%		99		4	%		38		17	%		61
PROSCAR		-30	%		90		-77	%		8		-13	%		82
TIMOPTIC / TIMOPTIC XE		-7	%		28		-17	%		2		-7	%		27
VASOTEC / VASERETIC		-11	%		119		N/A			—		-11	%		119
ZOLINZA		*			3		*			3		N/A			—

*	100% or over
N/A	- Not Applicable
(1)	- Includes ProQuad, M-M-R II and Varivax.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	3Q '07		% CHG.			VOL		PX		FX
TOTAL PHARMACEUTICAL SALES	$6,074		12		%	9		1		2
U.S. ($ MM)		3,767		16	%		12		4		N/A
Foreign ($ MM)		2,307		7	%		5		-3		5

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SEPTEMBER YEAR-TO-DATE
2007

NET PRODUCT SALES DETAIL (millions of dollars)

	SEPTEMBER YTD `07 vs. SEPTEMBER YTD `06
	TOTAL			TOTAL		U.S.			U.S.		Foreign			Foreign
PRODUCT	% CHG			$		% CHG			$		% CHG			$
COZAAR / HYZAAR		7	%		2,459		10	%		907		5	%		1,552
FOSAMAX		-4	%		2,253		—			1,460		-10	%		793
SINGULAIR		19	%		3,112		16	%		2,196		25	%		916
ZOCOR		-73	%		654		-93	%		128		-24	%		527
Vaccines:
GARDASIL		*			1,141		*			925		*			216
ROTATEQ		*			375		*			357		*			18
ZOSTAVAX		*			151		*			151		N/A			—
OTHER VIRAL VACCINES(1)		73	%		1,018		83	%		966		-14	%		52
HEPATITIS VACCINES		21	%		219		28	%		185		-5	%		34
OTHER VACCINES		29	%		285		21	%		213		61	%		72
Other Reported Products:
AGGRASTAT		-4	%		65		N/A			—		-4	%		65
ARCOXIA		28	%		245		N/A			—		28	%		245
CANCIDAS		2	%		403		-37	%		107		31	%		296
COSOPT / TRUSOPT		11	%		575		12	%		254		10	%		321
CRIXIVAN / STOCRIN		-4	%		230		-15	%		16		-3	%		214
EMEND		51	%		144		37	%		101		*			43
INVANZ		39	%		137		29	%		76		55	%		62
JANUVIA		*			415		*			391		*			25
JANUMET		*			43		*			41		*			2
MAXALT		16	%		341		19	%		230		9	%		112
PRIMAXIN		9	%		568		3	%		159		11	%		410
PROPECIA		18	%		293		5	%		113		27	%		179
PROSCAR		-34	%		328		-75	%		54		-2	%		274
TIMOPTIC / TIMOPTIC XE		-6	%		88		-13	%		6		-6	%		82
VASOTEC / VASERETIC		-10	%		369		N/A			—		-10	%		369
ZOLINZA		*			8		*			8		N/A			—

*	100% or over
N/A	- Not Applicable
(1)	- Includes ProQuad, M-M-R II and Varivax.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	SEP YTD `07		% CHG.			VOL		PX		FX
TOTAL PHARMACEUTICAL SALES	$17,955		8		%	6		—		2
U.S. ($ MM)		10,969		9	%		7		3		N/A
Foreign ($ MM)		6,986		6	%		5		-3		5